Bazzan M, Tamponi G, Gallo E, Stella S, Schinco P C, Pannocchia A, Pileri A
Department of Medicine and Experimental Oncology, Division of Hematology, Turin, Italy.
Haemostasis. 1993;23(1):38-44. doi: 10.1159/000216850.
Thrombotic and hemorrhagic complications are frequent in patients with essential thrombocythemia (ET), a myeloproliferative syndrome with an increased number of circulating platelets. Since platelets are a physiological reservoir for the plasminogen activator inhibitor (PAI-1) contained in plasma, we evaluated plasma and platelet tissue plasminogen activator (tPA) and PAI-1 in 20 ET patients with and without thrombotic complications and in 13 control subjects. In ET patients with thrombotic complications there was a significantly greater platelet PAI-1 functional activity than in ET patients without thrombotic complications and in the control group (p < 0.05 and p < 0.025, respectively). Moreover, platelet tPA activity was significantly low in all ET patients (p < 0.001). This fibrinolytic imbalance (increased plasminogen inhibitor and lowered activator) might be a critical cofactor in the thrombotic complications in ET patients.
血栓形成和出血并发症在原发性血小板增多症（ET）患者中很常见，ET是一种骨髓增殖综合征，其循环血小板数量增加。由于血小板是血浆中纤溶酶原激活物抑制剂（PAI-1）的生理储存库，我们评估了20例有或无血栓形成并发症的ET患者以及13名对照受试者的血浆和血小板组织纤溶酶原激活物（tPA）及PAI-1。有血栓形成并发症的ET患者的血小板PAI-1功能活性显著高于无血栓形成并发症的ET患者及对照组（分别为p < 0.05和p < 0.025）。此外，所有ET患者的血小板tPA活性均显著降低（p < 0.001）。这种纤溶失衡（纤溶酶原抑制剂增加而激活物降低）可能是ET患者血栓形成并发症的关键辅助因素。
